Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...
Yahoo Finance

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
GEN - Genetic Engineering and Biotechnology News

StockWatch: Recursion Slides on Data Update as New CEO Named

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
Yahoo Finance

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

NEW HAVEN, Conn., September 03, 2025--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for ...
TMCnet

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...
Finanznachrichten

Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...